VPTDF - Ventripoint Announces Patent Application for Improved Heart Analysis
(TheNewswire)
Toronto, Ontario – TheNewswire –August 09, 2021 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) has filed an international patent applicationunder the Patent Cooperation Treaty (PCT) to protect Ventripoint’s recent novel improvements to its cardiac measurement technology.Ventripoint is a pioneer in application of artificial intelligence(AI) to heart analysis and this latest application strengthens thecompany’s intellectual property position and coverage for theVentripoint’s flagship products. With this one internationalpatent application, Ventripoint registers its claim to this inventionin at least 153 different contracting countries under the PCT.
Dr. George Adams, CEO of Ventripoint, stated, “Thefiling of this latest patent application along with previous patentapplications and licenses builds a strong intellectual property (IP)estate. Technology companies are valued for their IP and Ventripointcontinues to pioneer novel ways to apply AI to cardiac analysis forthe betterment of patients, especially children, worldwide.”
The patent application has been filed under theinvention title “System, Method, and/or Computer-Readable Medium forMapping and Displaying Anatomical Structures in a User-FriendlyManner”. It claims a new, improved method of using 2D and 3Dechocardiography data for mapping and displaying the anatomicalstructure and configuration of the heart. A key novel component isthe use of templates with predetermined anatomical landmarks so thatmultiple anatomical features of the heart are alignedsimultaneously.
This upgrade to Ventripoint’s VMS+ products shortensthe analysis time for both 2D and 3D echocardiograms and will helpclinicians obtain more accurate and reliable results. The patentrelates to the method of using 2D and 3D echocardiography data formapping and displaying the anatomical structure of the heart for allfour pumping chambers of the heart.
Cardiovascular diseases continue to be the largestcause of death worldwide. Providing clinicians with the latestadvancements in diagnostic tools will play a pivotal role in combatingcardiovascular disease and sustaining robust hearts.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile andcan be used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe and Canada.
For further information, pleasecontact:
Mr. Peter Weichler
403-618-4016?
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2021 TheNewswire - All rights reserved.